That gap is the whole story. The switch from hCG to gonadorelin across telehealth TRT was driven by a regulatory change in March 2020, not by new evidence. If you care about fertility or testicular size on testosterone, the two drugs are not interchangeable. Below: what TRT does to the testes, what each add-on does about it, the human data, the regulatory picture as of November 2026, and what to ask your prescriber for.
Starting from
$79/mo
Free consultation

4.3 AHF · 4.8 Trustpilot
Solid telehealth TRT at the best price point with real-clinician care.
Get Started FreeWhat TRT does to LH, FSH and the testes
Your testes need two signals from the pituitary. Luteinising hormone (LH) tells the Leydig cells to make testosterone. Follicle-stimulating hormone (FSH) supports the Sertoli cells that nurse developing sperm. Both answer to gonadotropin-releasing hormone (GnRH) from the hypothalamus, and the loop runs on negative feedback: enough testosterone, and the brain turns the signal down.
Testosterone from a syringe, gel or pellet triggers that feedback just as your own does, so LH and FSH go nearly to zero. In the best-designed study on this question, healthy men given 200 mg of testosterone enanthate a week saw LH fall to 5% of baseline and FSH to 3% within three weeks [1].
The consequence that matters is inside the testis. Intratesticular testosterone (ITT) normally runs at roughly 80 times the level in your blood — in that same study, serum testosterone at baseline was just 1.2% of the testicular figure [1]. Sperm production depends on that local concentration, not on your blood level. With LH gone, the Leydig cells stop producing and ITT collapses: it fell 94% in the men on testosterone alone, from 1,234 to 72 nmol/L [1]. This is the paradox of TRT that surprises most men: your blood testosterone goes up while the testosterone inside your testes goes down.
Two things follow from that:
- Sperm counts fall. A retrospective review from Baylor's male fertility group puts azoospermia — no sperm in the ejaculate — at about 40% of men on TRT [2]. Many of the rest have reduced counts.
- The testes shrink. Most of testicular volume is the sperm-producing tubules. When FSH and ITT drop, the tubules quiet down and volume follows.
The good news, from contraceptive trials in healthy volunteers, is that suppression is usually reversible. An integrated analysis of 1,549 men across 30 studies found the probability of sperm counts recovering to 20 million/mL was 67% within six months of stopping, 90% within 12 months and 100% within 24 months [3]. That is reassuring but it is not a guarantee for you: those were young, fertile volunteers on defined courses, not men who have been on TRT for years, and longer treatment was one of the factors that slowed recovery [3].
So the question an add-on drug has to answer is simple: can it keep the testes working while the pituitary is switched off? hCG and gonadorelin try to do that in fundamentally different ways.
Gonadorelin vs hCG: two different mechanisms
hCG bypasses the brain. Human chorionic gonadotropin is structurally close to LH and acts on the same receptor in the testis. It does not need the pituitary to do anything. On TRT, the pituitary is suppressed, and hCG simply stands in for the missing LH signal at the Leydig cell, which restarts local testosterone production. What hCG does not do is replace FSH. It drives ITT, and ITT supports sperm production, but the FSH arm of the system stays low.
Gonadorelin goes through the brain. Gonadorelin is synthetic GnRH — the identical ten-amino-acid peptide the hypothalamus makes. It works one step upstream: it asks the pituitary to release its own LH and FSH. In principle, that is an edge over hCG, because it should restore both signals rather than one. In practice, it runs into two problems that hCG does not have.
The first problem is the dosing pattern the pituitary demands. The classic experiment, published in Science in 1978, used monkeys whose own GnRH had been abolished. A constant infusion of GnRH failed to restore gonadotropin secretion. The same hormone given in a brief pulse once an hour, matching the natural rhythm, brought it back. And switching animals from pulses to continuous exposure shut the system down again — the pituitary "desensitised" [4]. The pattern of delivery mattered more than the dose.
The second problem is how briefly gonadorelin lasts. In human infusion studies, native GnRH clears from the blood with a rapid half-disappearance time of about 8 minutes (7.8 ± 1.1 min) [5]. Each injection therefore produces a short LH pulse and then nothing. To mimic the hypothalamus, you need a new pulse every hour or two, day and night.
That is exactly how gonadorelin is used when it works. In a 2025 study from West China Second University Hospital, men with congenital hypogonadotropic hypogonadism wore a subcutaneous pump delivering 10–15 µg of gonadorelin every 90 minutes [6] — sixteen pulses a day, adjusted to keep LH and FSH in range. Compare that with the one or a few daily injections that telehealth gonadorelin protocols are typically built around. Whatever such an injection does, it is clearly not recreating the rhythm the 1978 experiment showed the pituitary needs.
The human evidence for hCG on TRT
The evidence for hCG alongside testosterone is not large, but it exists, it is human, and it measures the thing we care about.
The ITT trial. The 2005 study already cited is the anchor [1]. Twenty-nine healthy men were randomised to weekly testosterone enanthate plus either saline or hCG at 125, 250 or 500 IU every other day for three weeks, with testicular fluid sampled by fine-needle aspiration before and after. On testosterone plus placebo, ITT dropped 94%. With hCG, ITT rose in a clear dose-response line [1]:
| Arm (with 200 mg testosterone enanthate weekly) | ITT at 3 weeks vs baseline |
|---|---|
| Saline placebo | 94% lower |
| hCG 125 IU every other day | 25% lower |
| hCG 250 IU every other day | 7% lower |
| hCG 500 IU every other day | 26% higher |
That is a randomised result showing modest doses of hCG hold intratesticular testosterone at or near normal while the pituitary is fully suppressed. Its limits are real: three weeks, healthy volunteers, and it measured ITT, not sperm counts or pregnancies.
The fertility case series. The Baylor group then looked back at 26 hypogonadal men, mean age 35.9, treated with testosterone (injection or gel) plus 500 IU of hCG every other day [2]. Over a mean of 6.2 months of follow-up, and longer in some, semen parameters did not change from baseline, no man became azoospermic, and nine of the 26 contributed to a pregnancy with their partner during follow-up [2]. It is a retrospective chart review without a control group, so it cannot say how many of those men would have stayed fertile without hCG. Against a background azoospermia rate of roughly 40% on TRT, though, zero out of 26 is a meaningful signal.
Recovery after testosterone. hCG also has a role after the fact. In a series of 49 men who had become azoospermic or severely oligospermic on testosterone, hCG-based combination therapy (3,000 units every other day plus a SERM, aromatase inhibitor or FSH at physician discretion) was followed by a return of sperm in 47, at an average of 4.6 months [19]. Again a case series, again uncontrolled — but it is why fertility urologists reach for hCG first.
None of this is a large randomised fertility trial, and with hCG old and off-patent, nobody is likely to run one. The honest summary: a plausible mechanism, a randomised trial on the surrogate endpoint, and consistent clinical series on the real one.
The human evidence for gonadorelin on TRT
We searched PubMed and ClinicalTrials.gov for any study of gonadorelin given alongside testosterone therapy to preserve testicular function or fertility. We found none — no randomised trial, no case series, no registered study. Most clinic pages selling gonadorelin leave that out.
What does exist is evidence for pulsatile GnRH in a different population. Men with congenital hypogonadotropic hypogonadism (CHH) are born without a working GnRH signal, and for them a gonadorelin pump is an established treatment. In the 2025 West China cohort of 155 such men, pulsatile gonadorelin and hCG-plus-hMG injections induced sperm at similar rates (82.1% vs 75.8%, not a statistically significant difference), with the pump getting there faster (12.3 vs 14.7 months) and producing larger testes at the end (15 vs 12 mL total) [6]. That is a genuinely good result for gonadorelin — when it is delivered by pump, every 90 minutes, to men whose pituitary is not being suppressed by external testosterone.
Neither condition holds for a man on TRT taking an injection or two a day. His pituitary is being actively told to stand down by high circulating testosterone. Whether a short gonadorelin pulse can push through that feedback enough to keep ITT and FSH meaningfully up has not been measured.
Independent reviews land in the same place. A 2026 narrative review of peptide strategies for TRT-induced reproductive suppression rates the clinical evidence for GnRH and gonadorelin as "limited," notes that efficacy "depends on physiological pulsatile administration," and says GnRH therapy is reserved for specific indications "rather than routine management of TRT-induced reproductive suppression" [7]. A 2025 review of fertility-sparing options for hypogonadal men concludes that GnRH "can successfully induce spermatogenesis but is impractical to administer," while gonadotropins such as hCG can successfully induce fertility [20].
Clinics that prescribe gonadorelin will tell you their patients' testes do not shrink. Some may be right, but that rests on clinical impression, not published measurement — and nobody has shown it preserves fertility.
Why telehealth clinics switched from hCG to gonadorelin
If hCG has the better evidence, why did so many TRT services move away from it? Because in March 2020 compounded hCG effectively stopped being available.
hCG became a biologic. On March 23, 2020, under the Biologics Price Competition and Innovation Act, a group of protein drugs that had been approved as ordinary drugs were reclassified as biological products. FDA's notice to compounders named human chorionic gonadotropin among the bulk substances affected and stated that these products "will not be eligible for the exemptions for compounded drugs under sections 503A and 503B" [10]. Compounding pharmacies, which had supplied much of the cheap hCG used in cash-pay TRT, could no longer make it from bulk powder.
What remained was FDA-approved chorionic gonadotropin — a 10,000-unit multi-dose vial labelled for intramuscular use [11]. Its approved indications in men are prepubertal cryptorchidism and "selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency)" [11]. Use alongside TRT is off-label, which doctors are allowed to prescribe but which means the label offers no dose for it. The label also lists gynecomastia among adverse reactions and notes that hCG can interfere with LH lab assays [11]. The approved product costs more than the compounded version did, and that price pressure pushed a lot of clinics to look elsewhere.
Gonadorelin filled the gap. Gonadorelin is a small peptide, not a biologic, so it was untouched by the 2020 transition. Its regulatory position today is unusual, and worth stating carefully:
- There is no FDA-approved gonadorelin product on the market. Drugs@FDA lists both US brands — Factrel (gonadorelin hydrochloride) and Lutrepulse (gonadorelin acetate) — as discontinued [8][9].
- It is sold through 503A compounding pharmacies. Federal law lets a 503A pharmacy compound from a bulk substance that has a USP monograph, is a component of an FDA-approved drug, or is on FDA's 503A bulks list [12]. Gonadorelin was a component of approved drugs [8][9], and pharmacies compound it on that footing. We found no FDA statement addressing gonadorelin specifically.
- It is not on FDA's list of nominated bulk substances. Gonadorelin does not appear in any of the three categories in FDA's current list, last updated May 14, 2026 [13].
- It is not part of the new HHS peptide policy. On October 30, 2026, HHS published an enforcement-discretion policy for compounding certain peptides while the 503A bulks list is developed through rulemaking [14]. It covers six peptides — BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 [15]. Gonadorelin is not one of them, and the policy does not change its status either way.
So the switch was a supply decision: a drug pharmacies could still make cheaply replaced one they could not. That is a legitimate business reason, not a clinical one.
What the clinical guidelines say
Neither the American Urological Association nor the AUA/ASRM male infertility panel recommends gonadorelin for this purpose. Both are clear on the bigger point.
The AUA testosterone deficiency guideline, published in 2018 and reviewed with its validity confirmed in 2024 [17], carries a strong recommendation that men actively trying to conceive should not receive exogenous testosterone, as summarised by Cleveland Clinic urologists [18]. For men with fertility concerns, the options it points to are drugs that support the body's own production: SERMs such as clomiphene, hCG, and aromatase inhibitors [18]. That same summary notes that among these, only hCG is FDA-approved for use in males [18].
The joint AUA/ASRM male infertility guideline went further in its 2024 amendment. Statement 42 was modified so that clinicians should not prescribe exogenous testosterone to men "interested in current and future fertility," and the supporting text on hCG dosing and frequency for initial treatment was updated [16].
Read together, the guidelines' position is not "TRT plus the right add-on." It is: if fertility is a near-term goal, the first-line answer is to avoid suppressing the axis in the first place. hCG appears in that toolkit. Gonadorelin does not.
What a man on TRT should ask for
This is where we take a position. If you want to keep fertility or testicular volume while on testosterone, here is what we would ask a prescriber, in order of priority.
1. "If fertility matters in the next year or two, should I be on TRT at all?" This is the question the guidelines want asked first [16][17]. For a man with secondary hypogonadism whose testes still work, a SERM such as enclomiphene or clomiphene raises testosterone by turning LH and FSH up rather than down. It is a different trade-off, not a free lunch — our TRT vs enclomiphene for fertility and TRT vs clomid pieces cover it — but it is clearly the better choice for a man actively trying to conceive.
2. "If I stay on TRT, can I have hCG rather than gonadorelin?" hCG wins on evidence: a randomised ITT trial [1], a fertility case series with zero azoospermia [2], guideline support [18], and an FDA-approved product [11]. Gonadorelin has a plausible mechanism and an evidence base in a different population delivered in a different way [6]. Compared to gonadorelin, hCG is the better-supported choice for anyone whose priority is sperm rather than just testicular size. Expect it to cost more, and expect an intramuscular product per the label.
3. "What will we measure, and when?" Neither drug should be judged by feel. Ask for a baseline semen analysis before starting TRT, if you can still get one, and a repeat on treatment. Ask for LH and FSH. On hCG, LH readings can be misleading because hCG cross-reacts with LH assays [11] — your prescriber should know that. If a clinic tells you gonadorelin is working, ask what it measured to know.
4. "Should I bank sperm?" If you are already on TRT and want children later, a semen analysis now tells you where you stand. Freezing a sample is cheap insurance relative to the uncertainty, especially given that recovery takes longer the longer you have been on testosterone [3].
5. "If gonadorelin is what you offer, why?" A good answer sounds like: "It's what our pharmacy can supply; the evidence is weaker than for hCG; here's how we'll monitor it." A bad answer is that gonadorelin is "more natural" or "better than hCG." Nothing published supports the second claim.
If your current clinic cannot have that conversation, it may be worth comparing. PeterMD lists hCG among its TRT services, and Maximus offers enclomiphene as a non-suppressive route alongside injectable testosterone. Hims leads with enclomiphene for testosterone support. MangoRx, DudeMeds and Roman are other telehealth TRT options worth asking the same five questions. Offerings change, so confirm what each one prescribes before you sign up. You can compare TRT providers side by side, and our hormone optimization hub covers the in-person route. For men who have already stopped, our week-by-week recovery timeline after testosterone cypionate explains what to expect.
The bottom line: hCG is an old drug with modest but real human evidence for doing exactly what men on TRT want it to do. Gonadorelin is an old drug being used in a new way that nobody has tested. The second may turn out to work. Until someone publishes the study, it should not be sold to you as the equal of the first.
Frequently asked questions
Is gonadorelin as good as hCG on TRT?
Nobody knows, because the comparison has never been studied. hCG has a randomised trial showing it maintains intratesticular testosterone on TRT [1] and a case series in which no man became azoospermic [2]. We found no published study of gonadorelin in men on TRT. Pulsatile gonadorelin works well in men with congenital GnRH deficiency, but delivered by pump every 90 minutes [6].
Why did my TRT clinic switch me from hCG to gonadorelin?
Most likely supply and cost. When hCG was reclassified as a biologic on March 23, 2020, compounding pharmacies lost the ability to make it [10]. Gonadorelin, a small peptide, can still be compounded [12]. The switch reflected what pharmacies could make, not new evidence that gonadorelin works better.
Is gonadorelin FDA-approved?
No gonadorelin product is currently marketed in the US. Both FDA-approved versions, Factrel and Lutrepulse, are listed as discontinued [8][9]. What clinics prescribe is compounded. It is not among the six peptides in HHS's October 2026 compounding policy [14][15].
Does hCG prevent testicular shrinkage on TRT?
It addresses the cause. Shrinkage follows the collapse of LH-driven testosterone production inside the testis, and hCG replaces that LH signal — keeping intratesticular testosterone near baseline in the 2005 trial [1]. That trial measured testosterone in the testis, not volume, so direct volume data on TRT plus hCG are thin.
Can I stay fertile on TRT if I take hCG?
Possibly, but it is not guaranteed. In one 26-man series on TRT plus hCG, none became azoospermic and nine contributed to a pregnancy [2]. Current AUA/ASRM guidance says men interested in current or future fertility should not be prescribed testosterone at all [16], so ask about a SERM-based approach first.
Will my sperm come back if I stop TRT?
Usually. In pooled contraceptive-trial data, 67% of men recovered to 20 million/mL within six months and 100% within two years [3]. Longer use slows recovery [3], and hCG-based therapy has restored sperm in most men in clinical series [19]. A semen analysis tells you where you stand.
Sources
- [1] Coviello et al., Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression, J Clin Endocrinol Metab, 2005
- [2] Hsieh et al., Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy, J Urol, 2013
- [3] Liu et al., Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis, Lancet, 2006
- [4] Belchetz et al., Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone, Science, 1978
- [5] Barron, Millar and Searle, Metabolic clearance and plasma half-disappearance time of D-Trp6 and exogenous luteinizing hormone-releasing hormone, J Clin Endocrinol Metab, 1982
- [6] Zheng et al., Comparison of outcomes between pulsatile GnRH and combined gonadotropin therapy of spermatogenesis in patients with congenital hypogonadotropic hypogonadism, Reprod Biol Endocrinol, 2025
- [7] Cretu et al., Emerging peptide and neuroendocrine strategies for TRT-induced reproductive suppression and functional male hypogonadism: a narrative review, Front Reprod Health, 2026
- [8] Drugs@FDA, Factrel (gonadorelin hydrochloride), NDA 018123
- [9] Drugs@FDA, Lutrepulse (gonadorelin acetate), NDA 019687
- [10] FDA, Notice to compounders: changes that affect compounding as of March 23, 2020
- [11] Chorionic gonadotropin for injection, US prescribing information, DailyMed
- [12] FDA, Bulk drug substances used in compounding under section 503A of the FD&C Act
- [13] FDA, Bulk drug substances nominated for use in compounding under section 503A, updated May 14, 2026
- [14] HHS, Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, Federal Register, October 30, 2026
- [15] Foley & Lardner, HHS announces limited enforcement discretion for compounding of six peptides, October 2026
- [16] AUA, Male infertility guideline (AUA/ASRM), 2024 amendment summary
- [17] Mulhall et al., Evaluation and management of testosterone deficiency: AUA guideline, J Urol, 2018
- [18] Shumaker et al., Does my patient have testosterone deficiency?, Cleveland Clinic Journal of Medicine, 2024
- [19] Wenker et al., The use of HCG-based combination therapy for recovery of spermatogenesis after testosterone use, J Sex Med, 2015
- [20] Lockie et al., Diagnosis and treatment of hypogonadism in men seeking to preserve fertility — what are the options?, Int J Impot Res, 2025
Alpha Health Finder Editorial Team
Editorial Team
The Alpha Health Finder editorial team researches and writes evidence-based men's health content. Articles are grounded in cited primary sources and reviewed against a fixed editorial standard before publication. We are a research and directory team — not your prescribing clinicians.
Looking for an online provider?
Find a qualified online provider — compare options vetted and reviewed by Alpha Health Finder.
One email a week. The research, not the hype.
What we published this week, what we changed our minds about, and what it means if you are on a protocol.
No spam, no selling your address. Unsubscribe in one click.




